Triple-positive breast cancer involves tumors positive for estrogen, progesterone, and HER2 receptors, affecting treatment decisions and strategies. Diagnosis includes imaging and biopsy to confirm ...
—Building off of earlier findings, researchers sought to determine rates of neoadjuvant systemic therapy (NST) among U.S. women with cT1–2 N0 M0 HER2-positive breast cancer and identify factors ...
Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about a year. This time, the drug that delivered the positive readout is Tukysa, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results